BioInvent International AB's revenue for the
three
months ended in Mar. 2024 was kr5.94 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr61.15 Mil.
BioInvent International AB's Revenue per Share for the
three
months ended in Mar. 2024 was kr0.09.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.93.
Warning Sign:
BioInvent International AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of BioInvent International AB was -83.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -40.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -18.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -19.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, BioInvent International AB's highest 3-Year average Revenue per Share Growth Rate was 72.00% per year. The lowest was -49.60% per year. And the median was -24.60% per year.
BioInvent International AB Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioInvent International AB's Revenue
For the Biotechnology subindustry, BioInvent International AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Revenue distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Revenue falls into.
BioInvent International AB Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr61.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (OSTO:BINV) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioInvent International AB Revenue Related Terms
Thank you for viewing the detailed overview of BioInvent International AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioInvent International AB (OSTO:BINV) Business Description
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:BINV has been successfully added to your 